-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda Pharmaceutical Data From Phase 2b Trial Of Oveporexton In People With Narcolepsy Type 1 Published In New England Journal Of Medicine

Benzinga·05/14/2025 21:04:24
Listen to the news

–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated

–Oveporexton Found to be Generally Safe and Well Tolerated

–Phase 3 Readout of Oveporexton Anticipated in 2025